国家层面丙型肝炎病毒消除政策与策略:台湾经验
台湾抗-HCV估计患病率为3.1%,医源性行为是主要传播途径,在终末期肾病、HIV感染、注射吸毒者及阿片替代治疗人群中最高。约405,160例患者HCV RNA阳性需治疗。台湾政府提出2025年达到WHO 2030年HCV消除目标,并着力解决政治承诺、可持续筹资、减少报销限制、建立监测及特定人群微消除等障碍。
要点
- 台湾抗-HCV估计患病率3.1%,医源性行为是主要传播途径。
- 约405,160例患者HCV RNA阳性且需治疗。
- 台湾政府提出2025年达到WHO 2030年HCV消除目标。
核心结论
- 台湾政府提出2025年达到WHO 2030年HCV消除目标,并希望提前实现该目标。
研究设计与样本
- 本文为台湾国家层面HCV消除政策与策略的经验报告,未报告研究设计与样本量。
主要发现
- 台湾抗-HCV估计患病率为3.1%。
- 医源性行为是主要传播途径。
- 抗-HCV患病率在终末期肾病、HIV感染、注射吸毒者及阿片替代治疗人群中最高。
- 约405,160例患者HCV RNA阳性且需治疗。
关键数值与推荐
- HCV消除障碍包括政治承诺、可持续筹资、减少报销限制、建立监测及特定人群微消除。
- HCV消除最后阶段为加速45-79岁人群普遍HCV筛查并解决HCV感染不知晓问题。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The estimated prevalence of anti-HCV was 3.1% in Taiwan. Studies have shown iatrogenic behavior was the major transmission route. It is highest in specific populations including patients with end stage renal disease (ESRD), human immunodeficiency virus infection, who inject drug (PWID), and under opioid substitution treatment. Approximately 405,160 patients were seropositive for HCV RNA and in need of treatment. Taiwan government claims to reach WHO's 2030 goal of HCV elimination by 2025 and works hard to resolve several barriers of HCV elimination including political commitment, sustainable financing, minimize reimbursement restrictions, instituted monitoring, and perform micro-elimination of specific populations. The last stage of HCV elimination is to accelerate the universal HCV screening program of populations aged 45-79 years and resolve the unawareness issue of HCV infection. Hopefully, we can achieve the targets of HCV elimination set by WHO and reach the goal earlier in 2025.
引用
- Chien RN, Lu SN, Hui-Min Wu G, et al. Policy and Strategy for Hepatitis C Virus Elimination at the National Level: Experience in Taiwan. J Infect Dis. 2023. PMID: 37703347. doi:10.1093/infdis/jiad016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。